First Reported Case of Liver Damage Caused by Tirzepatide in a Patient with Metabolic Syndrome | Research

The takeaway

A 37-year-old woman with metabolic syndrome developed elevated liver enzymes attributed to tirzepatide use, marking the first reported case of tirzepatide-induced hepatotoxicity despite the drug's known liver fat-reducing properties.

First reported hepatotoxicity case
Tirzepatide-induced liver enzyme elevation in a 37-year-old, paradoxically despite the drug's liver-protective reputation

What the researchers found

First reported case of tirzepatide-induced hepatotoxicity in a 37-year-old woman with metabolic syndrome, notable because tirzepatide typically reduces liver fat content.

Why it matters

As tirzepatide prescriptions rapidly increase for both diabetes and obesity, clinicians need to be aware that liver damage is a possible adverse effect — even though the drug generally improves liver metrics. Liver function monitoring should be part of routine care.

The numbers in context

First reported case in the literature. Tirzepatide was recently FDA-approved for both type 2 diabetes and obesity.

How the study worked

Single case report documenting clinical presentation of elevated liver enzymes, diagnostic workup to exclude other causes, and attribution to tirzepatide use.

Who was studied

Single patient with type 2 diabetes on tirzepatide

What this study cannot tell us

Single case report — cannot determine incidence or risk factors. The mechanism of hepatotoxicity was not investigated. Other contributing factors to liver enzyme elevation may not have been fully excluded. The temporal relationship supports but does not prove causation.

How to read the evidence

Preliminary evidence from a single case report. Establishes a safety signal for clinical awareness but cannot determine frequency or causation.

When this study was published

Published in 2024. Important early safety signal as tirzepatide prescriptions scale rapidly.

The bigger picture

Many metabolic drugs that generally benefit the liver can occasionally cause idiosyncratic liver injury. As tirzepatide joins the growing arsenal of GLP-1/GIP-based therapies, building a complete safety profile through pharmacovigilance is essential. This case contributes to that effort.

Questions still open

What is the mechanism of tirzepatide-induced hepatotoxicity — is it immunological or metabolic?
Should routine liver function testing be recommended for all patients starting tirzepatide?
Are patients with pre-existing metabolic syndrome at higher risk for this adverse effect?

Common questions

Doesn't tirzepatide usually help the liver?

Yes — studies have shown tirzepatide reduces liver fat content and is being investigated for fatty liver disease. However, as with many drugs that generally benefit an organ, rare cases of adverse effects can still occur. This paradox makes this case particularly noteworthy.

Should I worry about liver damage from tirzepatide?

This is a single case report — liver damage from tirzepatide appears to be very rare. However, it's reasonable to have baseline liver function tests before starting the medication and to report any symptoms like abdominal pain, dark urine, or yellowing of skin to your doctor.

Read the original research

A Rare Case of Tirzepatide-Induced Hepatotoxicity.

ACG case reports journal, 11(10), e01484

View on PubMed ↗Publisher’s paper ↗

Citation

Sohal, Aalam; Casanova, Luis; Kowdley, Kris V. (2024). A Rare Case of Tirzepatide-Induced Hepatotoxicity.. ACG case reports journal, 11(10), e01484. https://doi.org/10.14309/crj.0000000000001484